-+ 0.00%
-+ 0.00%
-+ 0.00%

Richter, Adalvo expand tirzepatide co-development partnership for diabetes, obesity care

PUBT·08/06/2026 06:15:30
Listen to the news
Richter, Adalvo expand tirzepatide co-development partnership for diabetes, obesity care
  • Richter expanded a global co-development partnership with Adalvo to develop generic tirzepatide injections for diabetes and obesity care.
  • FDA accepted for review two ANDAs for generic tirzepatide injection in the US, both filed at NCE-1.
  • Collaboration targets scale access as reference exclusivities expire, backed by shared investment, dual supply chain, cost-leadership focus.
  • Tirzepatide brands Mounjaro and Zepbound generated about USD 36.5 billion in combined 2025 sales, based on company reports.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gedeon Richter plc published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.